Syngene International Enhances Drug Discovery Capabilities
Syngene International, a leading contract research and manufacturing organization, is making significant strides in the field of drug discovery and development. Through recent investments in a dedicated peptide laboratory and the implementation of advanced automation technologies, the company is set to accelerate the process of bringing innovative therapies to market. This initiative underscores Syngene's commitment to enhancing its end-to-end services and supporting clients in the pharmaceutical and biotechnology sectors.
Investment in a Dedicated Peptide Laboratory
Robust Facilities for Advanced Peptide Production
The new peptide laboratory located in Bengaluru is designed to cater to the growing demand for diverse peptide-based therapies. This state-of-the-art facility can produce various molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates. Equipped with six automated peptide synthesizers and robotic arms, the lab significantly shortens project timelines while ensuring the quality and consistency of results.
The lab's capabilities include integrated Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid Chromatography (HPLC), and Liquid-Phase purification processes. These advancements offer clients a seamless transition from initial discovery to further development, making it easier for them to innovate.
Automating DMPK Operations for Efficiency
Alongside the peptide lab, Syngene is enhancing its Drug Metabolism and Pharmacokinetics (DMPK) operations through cutting-edge automation. This includes the use of robotic systems for high-throughput sample preparation, effectively reducing turnaround times from five days to just three days. The automation not only improves cost efficiency by 30% but also triples the sample capacities, allowing clients to access critical data at a much faster pace.
Furthermore, the Direct-to-Biology (D2B) platform accelerates hit-to-lead optimization efforts by integrating rapid compound design with miniaturized synthesis and high-throughput screening. This approach saves substantial time, particularly for managing larger compound sets.
Supporting Partners with End-to-End Capabilities
Strategic Advances for Therapeutic Development
Peter Bains, Managing Director and CEO of Syngene International Limited, emphasized the company's dedication to integrating advanced technologies into research workflows. He mentioned, "At Syngene, we are committed to accelerating scientific discovery and improving operational efficiency through these innovations. By enhancing both throughput and reproducibility, we empower our scientists to focus on solving high-value problems for our clients."
The establishment of the dedicated peptide laboratory is a strategic move that positions Syngene to meet the increasing significance of peptides in therapeutic development. With comprehensive end-to-end capabilities, the facility will support partners from synthesis through purification to characterization and early-stage development.
Transforming the Drug Discovery Landscape
By merging advanced automation with substantial scientific expertise, Syngene International has crafted a robust platform that connects the drug discovery process with development and manufacturing. This comprehensive approach not only reinforces its collaborative model but also enhances the value provided to clients globally.
Showcasing Innovations at CPHI Frankfurt
Syngene will represent its advancements at the upcoming CPHI Frankfurt event. Attendees are invited to visit Syngene's booth at Ground Level, Hall Number 6, Booth Number C66, where the team will share detailed insights about its latest investments and capabilities in drug development.
About Syngene International
Syngene International Ltd. is an integrated research, development, and manufacturing service provider that caters to various sectors, including pharmaceuticals, biotechnology, and consumer goods. With over 5,600 scientists and expansive facilities encompassing more than 2.5 million square feet, Syngene focuses on delivering scientific excellence and robust data security to its global clientele. The company partners with around 400 clients, including prominent global names in the industry. This extensive experience positions Syngene as a leader in the field, greatly benefiting its partners through reduced time-to-market for innovative solutions.
Frequently Asked Questions
What is the primary purpose of Syngene's new peptide laboratory?
The peptide laboratory aims to enhance the production and development processes of peptide-based therapies efficiently and effectively.
How does automation impact Syngene's DMPK operations?
Automation in DMPK operations leads to faster sample preparation, improved cost efficiency, and increased sample capacity, enhancing overall operational effectiveness.
What innovations are showcased by Syngene at CPHI Frankfurt?
Syngene will present its recent advancements in drug discovery and development, focusing on its dedicated peptide lab and automation technologies.
Why are peptides increasingly important in therapeutic development?
Peptides play a vital role due to their therapeutic potential, as they offer unique properties that can be leveraged for various treatment options.
What distinguishes Syngene's service offerings?
Syngene is known for its integrated capabilities across research, development, and manufacturing, allowing for streamlined service and collaboration with clients.
